XNK Therapeutics AB raises 12.75m
XNK Therapeutics AB has secured a private placement of 12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Sanofi and IGM Biosciences Inc. in $6.15bn deal
/in News/by Thomas GabrielczykSanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
CSL Behring files for MAA of haemophilia B gene therapy
/in News/by Thomas GabrielczykCSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Argenx SE to raise 637m
/in News/by Thomas GabrielczykDutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Bayer invests into synthetic TCRs for cell therapy
/in News/by Thomas GabrielczykTCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Switzerland paves the way for genome editing
/in News/by Thomas GabrielczykSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches 517m
/in News/by Thomas GabrielczykGilde Healthcare Private Equity IV (GHPE IV) has closed at 517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
Precirix NV raises 80m in Series B financing
/in News/by Thomas GabrielczykWith 80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi bags 300m from US investor Blackstone
/in News/by Thomas GabrielczykSanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Join 900 US CEOs protest against Ukraine invasion
/in News/by Thomas GabrielczykUS Life Science leaders pledge to economically disengage from Russia.